Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection

Respiratory syncytial virus (RSV) is one of the most prevalent causative agents of lower respiratory tract infections worldwide, especially in infants around 3 to 4 months old. Infants at such a young age have maternally-transferred passive antibodies against RSV but do not have active immune system...

Full description

Bibliographic Details
Main Authors: Nao Jounai, Megumi Yoshioka, Miyuki Tozuka, Kazue Inoue, Tatsuya Oka, Kazuki Miyaji, Katsuyasu Ishida, Naoki Kawai, Hideyuki Ikematsu, Chiaki Kawakami, Hiroyuki Shimizu, Masaaki Mori, Ken J. Ishii, Fumihiko Takeshita
Format: Article
Language:English
Published: Elsevier 2017-02-01
Series:EBioMedicine
Subjects:
RSV
Online Access:http://www.sciencedirect.com/science/article/pii/S235239641730018X
id doaj-b40c38bc15cb4dbab430c322580a0d67
record_format Article
spelling doaj-b40c38bc15cb4dbab430c322580a0d672020-11-25T00:13:53ZengElsevierEBioMedicine2352-39642017-02-0116C12413510.1016/j.ebiom.2017.01.014Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus InfectionNao Jounai0Megumi Yoshioka1Miyuki Tozuka2Kazue Inoue3Tatsuya Oka4Kazuki Miyaji5Katsuyasu Ishida6Naoki Kawai7Hideyuki Ikematsu8Chiaki Kawakami9Hiroyuki Shimizu10Masaaki Mori11Ken J. Ishii12Fumihiko Takeshita13Kitasato Daiichi Sankyo Vaccine Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, JapanKitasato Daiichi Sankyo Vaccine Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, JapanKitasato Daiichi Sankyo Vaccine Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, JapanKitasato Daiichi Sankyo Vaccine Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, JapanKitasato Daiichi Sankyo Vaccine Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, JapanKitasato Daiichi Sankyo Vaccine Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, JapanDaiichi Sankyo Co., Ltd., 3-5-1 Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426, JapanJapan Physicians Association, 2-5 Kanda Surugadai, Chiyoda-ku, Tokyo 101-0062, JapanJapan Physicians Association, 2-5 Kanda Surugadai, Chiyoda-ku, Tokyo 101-0062, JapanDepartment of Pediatrics, Yokosuka Kyosai Hospital, 1-16 Yonegahamadori, Yokosuka, Kanagawa 238-8558, JapanChildren's Medical Center, Yokohama City University Medical Center, 4-57 Urafune, Minami-ku, Yokohama, Kanagawa 232-0024, JapanDepartment of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, JapanLaboratory of Adjuvant Innovation, National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8 Saito-Asagi, Ibaraki City, Osaka 567-0085, JapanDaiichi Sankyo Co., Ltd., 3-5-1 Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426, JapanRespiratory syncytial virus (RSV) is one of the most prevalent causative agents of lower respiratory tract infections worldwide, especially in infants around 3 to 4 months old. Infants at such a young age have maternally-transferred passive antibodies against RSV but do not have active immune systems efficient enough for the control of RSV infection. In order to elucidate age-specific profiles of immune responses against RSV protection, antibody responses were examined by using blood samples in both acute and convalescent phases obtained from child patients and adult patients. In addition to the serum neutralization activity, antibody responses to the RSV fusion protein (F protein) were dissected by analyzing levels of total IgG, IgG subclasses, the binding stability, and the levels of antibody for the neutralization epitopes. It was suggested that children's antibody responses against RSV are matured over months and years in at least 5 stages based on 1) levels of the neutralization titer and IgG3 for F protein in the convalescent phase, 2) geometric mean ratios of the neutralization titers and levels of IgG1 and IgG2 for F protein in the convalescent phase compared to those levels in the acute phase, 3) the affinity maturation of IgG for F protein and the cross reactivity of IgG for RSV glycoproteins of groups A and B, 4) levels of neutralization epitope-specific IgG, and 5) augmentation of overall antibody responses due to repetitive RSV infection.http://www.sciencedirect.com/science/article/pii/S235239641730018XRSVF proteinIgG3Palivizumab-like neutralization antibody
collection DOAJ
language English
format Article
sources DOAJ
author Nao Jounai
Megumi Yoshioka
Miyuki Tozuka
Kazue Inoue
Tatsuya Oka
Kazuki Miyaji
Katsuyasu Ishida
Naoki Kawai
Hideyuki Ikematsu
Chiaki Kawakami
Hiroyuki Shimizu
Masaaki Mori
Ken J. Ishii
Fumihiko Takeshita
spellingShingle Nao Jounai
Megumi Yoshioka
Miyuki Tozuka
Kazue Inoue
Tatsuya Oka
Kazuki Miyaji
Katsuyasu Ishida
Naoki Kawai
Hideyuki Ikematsu
Chiaki Kawakami
Hiroyuki Shimizu
Masaaki Mori
Ken J. Ishii
Fumihiko Takeshita
Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection
EBioMedicine
RSV
F protein
IgG3
Palivizumab-like neutralization antibody
author_facet Nao Jounai
Megumi Yoshioka
Miyuki Tozuka
Kazue Inoue
Tatsuya Oka
Kazuki Miyaji
Katsuyasu Ishida
Naoki Kawai
Hideyuki Ikematsu
Chiaki Kawakami
Hiroyuki Shimizu
Masaaki Mori
Ken J. Ishii
Fumihiko Takeshita
author_sort Nao Jounai
title Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection
title_short Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection
title_full Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection
title_fullStr Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection
title_full_unstemmed Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection
title_sort age-specific profiles of antibody responses against respiratory syncytial virus infection
publisher Elsevier
series EBioMedicine
issn 2352-3964
publishDate 2017-02-01
description Respiratory syncytial virus (RSV) is one of the most prevalent causative agents of lower respiratory tract infections worldwide, especially in infants around 3 to 4 months old. Infants at such a young age have maternally-transferred passive antibodies against RSV but do not have active immune systems efficient enough for the control of RSV infection. In order to elucidate age-specific profiles of immune responses against RSV protection, antibody responses were examined by using blood samples in both acute and convalescent phases obtained from child patients and adult patients. In addition to the serum neutralization activity, antibody responses to the RSV fusion protein (F protein) were dissected by analyzing levels of total IgG, IgG subclasses, the binding stability, and the levels of antibody for the neutralization epitopes. It was suggested that children's antibody responses against RSV are matured over months and years in at least 5 stages based on 1) levels of the neutralization titer and IgG3 for F protein in the convalescent phase, 2) geometric mean ratios of the neutralization titers and levels of IgG1 and IgG2 for F protein in the convalescent phase compared to those levels in the acute phase, 3) the affinity maturation of IgG for F protein and the cross reactivity of IgG for RSV glycoproteins of groups A and B, 4) levels of neutralization epitope-specific IgG, and 5) augmentation of overall antibody responses due to repetitive RSV infection.
topic RSV
F protein
IgG3
Palivizumab-like neutralization antibody
url http://www.sciencedirect.com/science/article/pii/S235239641730018X
work_keys_str_mv AT naojounai agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection
AT megumiyoshioka agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection
AT miyukitozuka agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection
AT kazueinoue agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection
AT tatsuyaoka agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection
AT kazukimiyaji agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection
AT katsuyasuishida agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection
AT naokikawai agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection
AT hideyukiikematsu agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection
AT chiakikawakami agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection
AT hiroyukishimizu agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection
AT masaakimori agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection
AT kenjishii agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection
AT fumihikotakeshita agespecificprofilesofantibodyresponsesagainstrespiratorysyncytialvirusinfection
_version_ 1725392555724505088